Dementia prevalence in Brazil is expected to increase by around 390% between 2001 and 2040.^[@r1]^ A definitive diagnosis of Alzheimer's disease (AD) requires both a clinical history of dementia and neuropathologic confirmation at autopsy. Given that age-related changes overlap with early changes in AD, it is important to adopt neuropathologic criteria able to reliably distinguish between these two conditions. The currently used neuropathologic staging models of AD have been developed in the last 20 years. While the relationship of the maximum frequency of neuritic plaques (NP) with the age of the subject associated to the history of dementia are the pivotal constituents of the Consortium to Establish a Registry for Alzheimer's Disease criteria (CERAD),^[@r2]^ the distribution and burden of neurofibrillary tangles (NFT) determine each of the seven Braak and Braak stages.^[@r3]^ Finally, the National Institute on Aging and the Ronald and Nancy Reagan Research Institute of the Alzheimer's Association^[@r4]^ proposed criteria for AD based on both NFT and NP (hereafter called NIA-Reagan criteria). The NIA-Reagan criteria stratifies cases by the likelihood that clinical dementia has been caused by AD lesions in the brain. [Table 1](#t1){ref-type="table"} gives a summary of these criteria.

###### 

Summary of the neuropathologic criteria of Alzheimer\'s disease.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Score name                              Stage                      Characteristics
  --------------------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------
  Braak and Braak\                        0\                         Brain devoid of NFT^[†](#TFN2){ref-type="table-fn"}^\
  stage (BB)                              I-II\                      NFT^[†](#TFN2){ref-type="table-fn"}^ in transentorhinal and entorhinal regions\
                                          III-IV\                    NFT^[†](#TFN2){ref-type="table-fn"}^ in the limbic allocortex and adjoining neocortex\
                                          V-VI                       NFT^[†](#TFN2){ref-type="table-fn"}^ in the neocortex, including the secondary and primary fields

  CERAD[\*](#TFN1){ref-type="table-fn"}   Normal                     No history of dementia and no NP^[‡](#TFN3){ref-type="table-fn"}^

                                          Possible\                  History of dementia and sparse number of NP^[‡](#TFN3){ref-type="table-fn"}^ (age-related), or\
                                          Probable\                  No history of dementia and moderate to severe number of NP (age-related)\
                                          Definitive                 History of dementia and sparse to moderate number of NP^[‡](#TFN3){ref-type="table-fn"}^ (age-related)\
                                                                     History of dementia and sparse to severe number of NP^[‡](#TFN3){ref-type="table-fn"}^ (age-related)

  NIA-Reagan                              Normal\                    BB=0 and CERAD= normal\
                                          Low likelihood\            BB=I/II and CERAD= possible\
                                          Intermediate likelihood\   BB=III/IV and CERAD= probable\
                                          High likelihood            BB=V/VI and CERAD= definitive
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CERAD: the consortium to establish a registry for Alzheimer\'s disease;

NFT: neurofibrillary tangles;

NP: neuritic plaques.

Although more than 10 years have passed since the last criteria were published, which of them best correlates with clinical symptoms remains a matter of debate. In addition, these criteria were largely tested in Caucasians of Northern European ancestry or in Asians^[@r5]-[@r7]^ and there may be biological differences in burden and distribution of AD changes among different ethnic groups.^[@r8]^ The Brazilian population is composed mainly of a mixture of Caucasians of Southern European ancestry, Africans and Indians. The purpose of this study was to examine which of the accepted neuropathologic criteria best discriminate AD from clinical normal aging in a clinicopathological series of 89 subjects belonging to the Brazilian Brain Bank of the Aging Brain Study Group (BBBABSG).

Methods
=======

A random sample of 89 retrospective cases belonging to the BBBABSG^[@r9]^ was studied. Brains were obtained from subjects aged 50 years or older sourced from the Sao Paulo Autopsy Service. Protocols were approved by the local ethics committee and written informed consent forms obtained.

The subjects' clinical and functional statuses were assessed through a reliable informant. The protocol included a series of semi-structured scales and questionnaires that covered major functional abilities and had been validated for assessment with an informant elsewhere.^[@r9]^ Clinical diagnosis of AD and vascular dementia were based on DSMIV-R and NINCDS-ADRDA,^[@r10]^ respectively as recommended by the Brazilian Academy of Neurology^[@r11]^. The usual criteria were used for other dementias.^[@r12],[@r13]^ Neuropathological examinations were carried out based on accepted criteria,^[@r9]^ using immunohistochemistry for β-amyloid (4G8), phospho-tau (PHF-1, gift from Peter Davies), α-synuclein (EQV-1, gift of Kenji Ueda) and where required, ubiquitin-1,

Out of the 89 cases, those having a neurodegenerative disease other than AD, or having dementia related to vascular changes were excluded.

The 62 remaining cases were divided into three groups according to the clinical dementia rating (CDR) score:^[@r14]^ CDR0=no cognitive decline; CDR0.5=questionable dementia and CDR≥1=dementia. The CDR groups were compared to the Braak and Braak stage, CERAD score and NIA-Reagan score.

Correlations were analyzed using the Spearman's rank correlation coefficient. The closer *r* is to one, the stronger the correlation. The *r* value was considered statistically significant when p\<0.05. Statistical analysis was performed using the software SPSS v. 13 (SPSS, Chicago, Illinois, USA).

Results
=======

The CDR distribution and demographic data of the 62 selected subjects are described in [Table 2](#t2){ref-type="table"}. There were no differences regarding age, gender and education among those groups.

###### 

Demographic data of the 62 subjects included in this study.

  ------------------------------------------------------------
  Cognitive status   Number\       Mean age\    Male:female\
                     of subjects   (in years)   (%)
  ------------------ ------------- ------------ --------------
  CDR 0              39            69.7±12.1    61.5:38.5

  CDR 0.5            9             71.6±12.3    66.7:33.3

  CDR ≥1             14            82.9±4,9     50:50

  Total              62            72.9±12.1    59.7:40.3
  ------------------------------------------------------------

[Table 3](#t3){ref-type="table"} depicts the distribution of the cases under each CDR group by the CERAD score, Braak and Braak stage and NIA-Reagan score. In 9 subjects, classification according to NIA-Reagan score was not possible due to discrepancies between CERAD score and Braak and Braak stage.

###### 

Distribution of the cases in each CDR group by the CERAD score, Braak and Braak stage and NIA-Reagan score.

                                                    CDR 0   CDR 0.5   CDR ≥1   TOTAL
  ----------------------- ------------------------- ------- --------- -------- -------
  CERAD score             Normal                    29      7         6        42
                          Possible                  5       0         2        7
                          Probable                  2       1         2        5
                          Definitive                3       1         4        8
  Braak and Braak stage   0                         18      2         1        21
                          I/II                      15      4         7        26
                          III/IV                    5       3         2        10
                          V/VI                      1       0         4        5
  NIA-Reagan score        Normal                    29      6         6        41
                          Low likelihood            0       1         1        2
                          Intermediate likelihood   4       0         2        6
                          High likelihood           1       0         3        4
                          Criteria not met          5       2         2        9

CDR: clinical dementia rating.

[Table 4](#t4){ref-type="table"} shows the correlation among CDR score and neuropathologic criteria. CERAD score correlated best to the CDR scale ([Table 4](#t4){ref-type="table"}).

###### 

Clinicopathological correlation by score. The r and p values are depicted on first and second lines, respectively.

  -----------------------------------------------------------------------------------------------------------------------------
  Score name        CDR[\*](#TFN5){ref-type="table-fn"}   CERAD[†](#TFN6){ref-type="table-fn"}   Braak and Braak   NIA-Reagan
  ----------------- ------------------------------------- -------------------------------------- ----------------- ------------
  CDR               1.0000                                                                                          

  CERAD             0.5303\                               1.0000                                                    
                    0.0000                                                                                         

  Braak and Braak   0.5294\                               0.7563\                                1.0000             
                    0.0000                                0.0000                                                   

  NIA-Reagan        0.5076\                               0.9189\                                0.9102\           1.0000
                    0.0002                                0.0000                                 0.0000            
  -----------------------------------------------------------------------------------------------------------------------------

CDR: clinical dementia rating;

CERAD: the consortium to establish a registry for Alzheimer\'s disease.

Discussion
==========

In this series, the CERAD criteria correlated to the CDR score better than Braak and Braak score and NIA-Reagan criteria, although this moderate correlation was only slightly better than for the Braak and Braak score. Results diverge in the literature, with McKeel et al. in 2004^[@r15]^ finding NPs to be the best marker to differentiate normal controls from questionable dementia subjects, corroborating previous results,^[@r6],[@r16]^ whereas some studies favor the Braak stage for best correlation to dementia severity.^[@r17]^

Despite the criteria, majority of studies comparing AD neuropathologic criteria have considered neurofibrillary tangle density and distribution to be directly proportional to severity of AD.^[@r18]-[@r20]^ The present study corroborates these findings. In our series, 7.7% of the CDR0 subjects met Braak stages ≥ IV, while 43% of the CDR≥ 1 subjects met the same stages.

The casuistic used to correlate NIA-Reagan criteria and CDR was reduced because nine subjects did not meet the criteria in order to be scored. NIA-Reagan criteria demand a perfect match between CERAD score and Braak stage. We are not the first to report problems in using the NIA-Reagan criteria. In 1997, Geddes et al. were only able to classify 22 out of their 47 cases using the NIA-Reagan criteria.^[@r21]^ They suggested accommodating discrepant cases having either a probable CERAD score or a limbic Braak and Braak stage, into the intermediate likelihood group of NIA-Reagan criteria. Also, Braak et al. in 1989 published results showing a mismatch between plaques and tangles in staging Alzheimer's pathology.^[@r22]^ Indeed, the r value of CEARD score and Braak and Braak stage correlation was 0.75. Therefore, the highly specific but low sensitivity NIA-Reagan criteria are most used for selecting well defined groups of cases for further analyses. If the prevalence of dementia of the casuistic is low or if the study focuses mainly on control subjects, specificity is usually the most important point and NIA-Reagan criteria are suggested for subject selection.

Perhaps, the current clinical criteria for AD might not be able to detect early changes. Corroborating this hypothesis, neuropathological diagnosis of AD was assigned to control clinical cases in several studies including the present.^[@r23],[@r24]^ On the other hand, NP and NFT may be merely markers of AD. Giannakopoulus et al. demonstrated, in a large series of pure AD cases, that more than 50% of CDR scale variability was not explained by NFT or by amyloid deposits.^[@r7]^

The present study also has limitations. Informant-based clinicofunctional data might not be reliable enough for detecting early clinical changes. In order to enhance the sensitivity of our interview to early clinical changes, the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)^[@r25]^ scale is used together with the CDR score. A study performed in Sao Paulo City verified the IQCODE's high sensitivity and specificity for the local population.^[@r26]^ Furthermore, evidence has shown these scales to be reliable even for subjects having mild cognitive impairment.^[@r27]^

In sum, this series involving Brazilian samples derived from a general autopsy service corroborates the results found in other clinicopathological series. These preliminary results show that our functional assessment has a good correlation with the neuropathological findings compared to other series. Nevertheless, the clinicopathological correlation is not yet ideal and further studies may reveal better markers and criteria.
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